<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04207957</url>
  </required_header>
  <id_info>
    <org_study_id>F901318-01-14</org_study_id>
    <nct_id>NCT04207957</nct_id>
  </id_info>
  <brief_title>A Biopharmaceutics Study to Assess the Pharmacokinetics of Single Oral and IV Doses of Olorofim</brief_title>
  <official_title>A Phase I, Open-label, Randomised Biopharmaceutics Study in Healthy Subjects to Evaluate the Pharmacokinetics, Safety and Tolerability of Single Doses of IV and Oral Formulations of Olorofim</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>F2G Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Covance</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>F2G Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I, single-centre, randomised, open-label, crossover study in 24 healthy
      subjects. Twelve subjects will each receive olorofim as a single IV infusion, single oral
      dose (fasted) and single oral dose (fed) and 12 subjects will each receive olorofim orally as
      intact tablets and via NG tube
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 5, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>3 Treatment Periods for Cohorts A and B 2 Treatment Periods for Cohort C</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>maximum plasma concentration (Cmax) for olorofim</measure>
    <time_frame>35 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>area under the concentration time curve to time of last quantifiable concentration (AUC0-tlast) for olorofim</measure>
    <time_frame>35 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute bioavailability of olorofim (F)</measure>
    <time_frame>35 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax (TMax) for olorofim</measure>
    <time_frame>35 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>area under the concentration time curve to infinity (AUC0-∞) for olorofim</measure>
    <time_frame>35 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>terminal elimination half-life (t½) for olorofim</measure>
    <time_frame>35 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with treatment-related adverse events</measure>
    <time_frame>35 days</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>IV</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>2 h IV infusion (Groups A/B)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oral (fasted)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>30 mg tablets given after an overnight fast (Groups A/B)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oral (fed)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>30 mg tablets given after a high fat breakfast (Groups A/B)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oral (intact tablet)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>30 mg tablets (Group C)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oral (NG tube)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>30 mg tablets in water via NG tube (Group C)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olorofim</intervention_name>
    <description>150 mg</description>
    <arm_group_label>IV</arm_group_label>
    <arm_group_label>oral (NG tube)</arm_group_label>
    <arm_group_label>oral (fasted)</arm_group_label>
    <arm_group_label>oral (fed)</arm_group_label>
    <arm_group_label>oral (intact tablet)</arm_group_label>
    <other_name>F901318</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  males or females of any ethnic origin between 18 and 55 years of age

          -  subjects weighing between 50 and 100 kg, with a body mass index (BMI) between 18 and
             30 kg/m2.

          -  subjects in good health, as determined by a medical history, physical examination,
             12-lead electrocardiogram (ECG) and clinical laboratory evaluations

        Exclusion Criteria:

          -  Male subjects (or their partners) who are not willing to use appropriate contraception
             during the study and for 3 months after end of dosing.

          -  Female subjects who are pregnant or lactating.

          -  Subjects who have received any prescribed systemic or topical medication within 14
             days of first dose administration

          -  Subjects who have used any non-prescribed systemic or topical medication within 7 days
             of first dose administration

          -  Subjects who have received any medications, including St John's Wort, known to
             chronically alter drug absorption or elimination processes within 30 days of first
             dose administration

          -  Subjects with or history of clinically significant neurological, gastrointestinal,
             renal, hepatic, cardiovascular, psychiatry, respiratory, metabolic, endocrine, ocular
             haematological or other major disorders as determined by the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jim Bush, MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance CRU</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen Cornelissen</last_name>
    <phone>07801353951</phone>
    <email>kcornelissen@f2g.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Covance Clinical Research Unit</name>
      <address>
        <city>Leeds</city>
        <state>West Yorkshire</state>
        <zip>LS2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Project Manager</last_name>
      <phone>0113 301 3500</phone>
    </contact>
    <investigator>
      <last_name>JIm Bush, MBChB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 19, 2019</study_first_submitted>
  <study_first_submitted_qc>December 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2019</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olorofim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

